GYRE THERAPEUTICS, INC. (GYRE)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 29, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, GYRE THERAPEUTICS, INC. reported revenue of $29.1M, net income of -$14.3M, and total assets of $199.3M. Every figure below is taken directly from GYRE THERAPEUTICS, INC.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2016–FY2025 · as reported
- FY2016 revenue
- $399,000
- FY2025 revenue
- $116.6M
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | $116.6M | $9.9M |
| FY2024 | $105.8M | $17.9M |
| FY2023 | $113.5M | -$85.5M |
| FY2022 | $102.3M | $4.3M |
| FY2021 | $7.3M | -$87.9M |
| FY2020 | $20.9M | -$56.2M |
| FY2019 | — | -$55.2M |
| FY2018 | $6,000 | -$30.1M |
| FY2017 | $1.0M | -$21.6M |
| FY2016 | $399,000 | -$16.9M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Oct 22, 2026 | on EDGAR ↗ |
| 8-K | Sep 1, 2026 | on EDGAR ↗ |
| 8-K | Aug 26, 2026 | on EDGAR ↗ |
| 8-K | Aug 7, 2026 | on EDGAR ↗ |
| 10-Q | Aug 7, 2026 | on EDGAR ↗ |
| 8-K | Jul 16, 2026 | on EDGAR ↗ |
| 8-K | Jun 16, 2026 | on EDGAR ↗ |
| 8-K | Jun 2, 2026 | on EDGAR ↗ |
| 8-K | May 14, 2026 | on EDGAR ↗ |
| 8-K | May 12, 2026 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $-0.12 | Earnings | source ↗ |
| EPS (basic) | $-0.12 | Earnings | source ↗ |
| Shares Outstanding | 111.5M | Entity | source ↗ |
| Cash from Operations | -$16.7M | Net | source ↗ |
| Cash from Financing | -$8,000 | Net | source ↗ |
| Cash from Investing | $9.8M | Net | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
- Buys
- 0
- Sells
- 18
- Net shares
- -147.7K
Restatement history
Point-in-time40 of 419 annual fact-keys were materially restated between filings: what GYRE THERAPEUTICS, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
Deeper fundamentals
A free API key reaches GYRE’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/GYRE
MCP tool:
get_sec_fundamentals ticker=GYRE - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/GYRE/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=GYRE as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/GYRE/history
MCP tool:
get_fundamentals_history ticker=GYRE - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/GYRE
MCP tool:
get_financial_health ticker=GYRE
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.